Comparing Dominari (DOMH) and Its Competitors

Dominari (NASDAQ:DOMH – Get Rating) is one of 44 publicly-traded companies in the “Commercial physical research” industry, but how does it contrast to its competitors? We will compare Dominari to related companies based on the strength of its dividends, risk, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Volatility & Risk

Dominari has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Dominari’s competitors have a beta of 4.90, meaning that their average share price is 390% more volatile than the S&P 500.

Profitability

This table compares Dominari and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dominari	N/A	-18.21%	-16.94%
Dominari Competitors	-244.63%	-12.67%	-6.96%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Dominari and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	0	0	0	0	N/A
Dominari Competitors	44	680	1259	25	2.63

As a group, “Commercial physical research” companies have a potential upside of 18.08%. Given Dominari’s competitors higher probable upside, analysts clearly believe Dominari has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares Dominari and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Dominari	N/A	-$7.17 million	-1.02
Dominari Competitors	$1.53 billion	$80.65 million	-14.31

Dominari’s competitors have higher revenue and earnings than Dominari. Dominari is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

10.9% of Dominari shares are owned by institutional investors. Comparatively, 56.5% of shares of all “Commercial physical research” companies are owned by institutional investors. 8.6% of Dominari shares are owned by insiders. Comparatively, 12.5% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Dominari competitors beat Dominari on 8 of the 9 factors compared.

About Dominari

(Get Rating)

Dominari Holdings, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. Its oncology therapeutics includes treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It also creates a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY.